Intec Pharma (NTEC) Stock Rating Lowered by Zacks Investment Research

Intec Pharma (NASDAQ:NTEC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “

A number of other research firms have also weighed in on NTEC. Oppenheimer set a $15.00 price objective on Intec Pharma and gave the stock a “buy” rating in a research note on Friday, October 13th. CIBC reissued an “outperform” rating and set a $15.00 price objective (up previously from $10.00) on shares of Intec Pharma in a research note on Thursday, September 21st. Maxim Group set a $8.00 price objective on Intec Pharma and gave the stock a “buy” rating in a research note on Friday, November 17th. Finally, ValuEngine lowered Intec Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $11.15.

Shares of Intec Pharma (NASDAQ NTEC) opened at $6.80 on Wednesday. Intec Pharma has a 12-month low of $4.20 and a 12-month high of $9.80.

Several institutional investors have recently made changes to their positions in NTEC. Sectoral Asset Management Inc acquired a new position in Intec Pharma during the 3rd quarter worth about $3,177,000. Caxton Corp acquired a new position in Intec Pharma during the 3rd quarter worth about $681,000. Pura Vida Investments LLC acquired a new position in Intec Pharma during the 3rd quarter worth about $895,000. Finally, Migdal Insurance & Financial Holdings Ltd. lifted its stake in Intec Pharma by 5.0% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 522,200 shares of the biotechnology company’s stock worth $2,977,000 after acquiring an additional 25,000 shares in the last quarter. 40.16% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.com-unik.info/2018/01/10/intec-pharma-ntec-stock-rating-lowered-by-zacks-investment-research.html.

About Intec Pharma

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit